[Lab] SGN survo — VendorInvestigate came back 93.7% against a claimed 98.6%
Right, the API source question again, but with numbers this time.
I have 4 data points over 12 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign.
The thing I would flag for anyone new: the effect I am describing showed up at week 28, not week 77. People give up long before the interesting part.
Interested in whether this matches other people's logs or whether I am an outlier.
best — the order this archive was captured in
Strongly agree. API source transparency matters.
regulatory claims need a citation to the actual rule, not interpretation
Yeah, 503A and 503B are different regulatory animals.
Small correction: the trial was 17 weeks, not 32. Does not change your point but people will quote it.
Small correction: the trial was 15 weeks, not 37. Does not change your point but people will quote it.
telehealth prescriber models exist, pricing differs by state
[removed by moderator]
You have restated the marketing copy. What is the actual substance here.
API transparency is the question that separates good compounders from sketchy ones
the the UK situation is different from the US, different regulations
API transparency is the question that separates good compounders from sketchy ones
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
shortage list status is 503B, check the actual list
the 503A/503B distinction is load-bearing, do not blur it
Asked 18 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.
Removed a chain here. The rule is one line long and it is not negotiable.
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
API source questions are on-topic and compounders dodging them is newsworthy
regulatory claims need a citation to the actual rule, not interpretation
Disagree but this is the good kind of wrong — it is specific enough to be checked.
API source questions are on-topic and compounders dodging them is newsworthy
API transparency is the question that separates good compounders from sketchy ones
the 503A/503B distinction is load-bearing, do not blur it
telehealth prescriber models exist, pricing differs by state
telehealth prescriber models exist, pricing differs by state
Yes, exactly this, and it is the bit that took me 82 weeks to accept.
API source questions are on-topic and compounders dodging them is newsworthy
This is correct. The shortage list does expire and the rules change.
This is the "correlation is mechanism" thing again. You changed three variables at once.
telehealth costs compounding plus compounding markup, total varies
You have restated the marketing copy. What is the actual substance here.
- 1regulatory claims need a citation to the actual rule, not interpretation12 comments in this branch · started by u/emil_okwuosa
- 2API source questions are on-topic and compounders dodging them is newsworthy5 comments in this branch · started by u/solene_eriksen